Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. Iland HJ, et al. Among authors: bashford j. Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. doi: 10.1182/blood-2012-02-410746. Epub 2012 Jun 19. Blood. 2012. PMID: 22715121 Free article. Clinical Trial.
High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group.
Morton J, Taylor K, Bunce I, Eliadis P, Rentoul A, Moore D, Kelly C, Wright S, Bashford J, Rodwell R, Rooney K, Mulligan S, Firkin F, Dodds A, Parkin J, Lowenthal R, Kimber R, Frost T, Grigg A, Goldstein D, Stone J, Lee N. Morton J, et al. Among authors: bashford j. Br J Haematol. 1996 Oct;95(1):110-5. doi: 10.1046/j.1365-2141.1996.d01-1868.x. Br J Haematol. 1996. PMID: 8857946
Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor.
Morton J, Mollee P, Taylor K, Grigg A, Durrant S, Moore D, Rodwell R, Eliadis P, Hutchins C, Williams B, Seeley G, Wright S, Kelly C, Rentoul A, Iland H, Atkinson K, Januszewicz H, Bunce I, Bashford J, Stewart C, Taylor D. Morton J, et al. Among authors: bashford j. Leuk Res. 1999 Feb;23(2):177-83. doi: 10.1016/s0145-2126(98)00143-x. Leuk Res. 1999. PMID: 10071133
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Bradstock K, Matthews J, Young G, Lowenthal R, Baxter H, Arthur C, Bashford J, Brighton T, Cannell P, Dunlop L, Durrant S, Enno A, Eliadis P, Gill D, Gillett A, Gottlieb D, Januszewicz H, Joshua D, Leahy M, Schwarer A, Taylor K; Australian Leukaemia Study Group. Bradstock K, et al. Among authors: bashford j. Leukemia. 2001 Sep;15(9):1331-8. doi: 10.1038/sj.leu.2402218. Leukemia. 2001. PMID: 11516093 Clinical Trial.
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T, Gill D, Eliadis P, Joshua D, Cannell P, Schwarer AP, Durrant S, Gillett A, Koutts J, Taylor K, Bashford J, Arthur C, Enno A, Dunlop L, Szer J, Leahy M, Juneja S, Young GA; Australasian Leukaemia and Lymphoma Group. Bradstock KF, et al. Among authors: bashford j. Blood. 2005 Jan 15;105(2):481-8. doi: 10.1182/blood-2004-01-0326. Epub 2004 Jun 22. Blood. 2005. PMID: 15213095 Free article. Clinical Trial.
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, Joske D, Grigg A, McKendrick J, Prosser I, Lowenthal R, Deveridge S, Taylor K; Australasian Leukemia and Lymphoma Group. Spencer A, et al. Among authors: bashford j. Bone Marrow Transplant. 2005 May;35(10):971-7. doi: 10.1038/sj.bmt.1704946. Bone Marrow Transplant. 2005. PMID: 15778725 Clinical Trial.
Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.
Grigg AP, Stone J, Milner AD, Schwarer AP, Wolf M, Prince HM, Seymour J, Gill D, Ellis D, Bashford J; Australasian Leukaemia & Lymphoma Group. Grigg AP, et al. Among authors: bashford j. Leuk Lymphoma. 2010 Apr;51(4):641-9. doi: 10.3109/10428191003611428. Leuk Lymphoma. 2010. PMID: 20218809 Clinical Trial.
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group. Iland H, et al. Haematologica. 2012 Feb;97(2):227-34. doi: 10.3324/haematol.2011.047506. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993673 Free PMC article. Clinical Trial.
143 results